-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
name -->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
McCray Paul B
2020-11-02
The proposed research is relevant to the public health because genetic and acquired diseases affecting the airways pose major disease and economic burdens. By advancing the delivery of gene editing tools, it may be possible to therapeutically modify the cells lining the airways. This novel strategy has implications for the treatment of both monogenetic and acquired lungs disease, and may have applications for other somatic cell therapies.
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
-->
RNA-guided CRISPR genome editing systems promise to revolutionize the treatment of inherited disease.
that directs editing is a critical hurdle in the development of clinical applications for engineered CRISPR
of nucleic acid therapeutics, we have established a framework for complete chemical modification of CRISPR
name -->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Sontheimer Erik J
2021-04-15
RNA-guided CRISPR genome editing systems promise to revolutionize the treatment of inherited disease. Safe, effective, and target-tissue-specific delivery of the guide RNA that directs editing is a critical hurdle in the development of clinical applications for engineered CRISPR systems. Using strategies validated for the delivery of other categories of nucleic acid therapeutics, we have established a framework for complete chemical modification of CRISPR guides, thereby conferring in vivo stability and effective biodistribution properties. The proposed research will optimize these guides, as well as other editing components, for clinical use.
|
-->
Enabling Nanoplatforms for Targeted In Vivo Delivery of CRISPR/Cas9 Riboncleoproteins in the Brain
-->
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain.
-->
Nanocapusules carrying CRISPR Cas9 RNP with guide RNA targeting the stop sequence in the Ai14 transgene
name -->
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain.
-->
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain.
Gong Shaoqin (Sarah)
2020-10-28
Nanocapusules carrying CRISPR Cas9 RNP with guide RNA targeting the stop sequence in the Ai14 transgene are intracerebrally delivered to Ai14 mice and gene editing is measured by gain of tdTomato protein expression.
|
-->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
name -->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
Gao Guang-Ping
2020-10-20
Efficacy and safety limitations in current gene editing technologies have hindered efforts to treat genetic lung diseases. This proposal seeks to develop and validate a combinatorial delivery approach that uses non-viral and viral vehicles to efficiently transport gene editing tools to disease-relevant cells in the lung. Completion of our work will establish safe and effective delivery vehicles that will guide the design of future gene therapies for genetic disorders.
|
-->
Enabling Nanoplatforms for Targeted In Vivo Delivery of CRISPR/Cas9 Riboncleoproteins in the Brain
-->
In vivo genome editing using CRISPR/Cas9 is anticipated to be the next wave of therapeutics for various
name -->
Enabling Nanoplatforms for Targeted In Vivo Delivery of CRISPR/Cas9 Riboncleoproteins in the Brain
Gong Shaoqin (Sarah)
2020-10-28
In vivo genome editing using CRISPR/Cas9 is anticipated to be the next wave of therapeutics for various major health threats, including neurodegenerative diseases. However, to date, very few Cas9-gRNA ribonucleoprotein in vivo delivery methods have been reported, and delivery to the brain has been particularly challenging. The unique nanocapsules we plan to develop will ultimately enable high efficiency neuron-targeted genome editing in the brain, thereby offering new hope to treat devastating neurodegenerative diseases.
|
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
-->
Expanding genome editing tools through exploration of new CRISPR-Cas proteins and DNA repair enzymes
NARRATIVE Fundamental research on bacterial adaptive immunity uncovered the genome editing properties of CRISPR-Cas
We will focus our investigation on newly described CRISPR-Cas systems and DNA-interacting proteins that
name -->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Banfield Jillian
, Doudna Jennifer A
2020-10-16
Expanding genome editing tools through exploration of new CRISPR-Cas proteins and DNA repair enzymes NARRATIVE Fundamental research on bacterial adaptive immunity uncovered the genome editing properties of CRISPR-Cas systems, and it is clear that uncultivated microbes contain more pathways and enzymes that may be useful as genome editing tools. We will combine bioinformatics and biochemistry to identify new DNA- and RNA-associating proteins and will analyze their mechanisms of action. We will focus our investigation on newly described CRISPR-Cas systems and DNA-interacting proteins that occur in conserved genomic context.
|
-->
Second site validation of Gong delivery platform using RNP-loaded nanocages to deliver CRISPR/Cas9 to
-->
Delivery of CRISPR/Cas9 via RNP-loaded nanocages to the brain in Ai14 mice
name -->
Second site validation of Gong delivery platform using RNP-loaded nanocages to deliver CRISPR/Cas9 to
-->
Second site validation of Gong delivery platform using RNP-loaded nanocages to deliver CRISPR/Cas9 to
Murray Stephen A
2021-04-01
Delivery of CRISPR/Cas9 via RNP-loaded nanocages to the brain in Ai14 mice
|
-->
Validation for McCray Delivery Team: Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using
-->
Ribonucleoproteins for CRISPR/Cas9 editing are complexed with amphiphilic peptides for delivery to lung
name -->
Validation for McCray Delivery Team: Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using
-->
Validation for McCray Delivery Team: Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using
Heaney Jason D
2021-09-07
Ribonucleoproteins for CRISPR/Cas9 editing are complexed with amphiphilic peptides for delivery to lung airway epithilia via intranasal instillation into mTmG reporter mice. Editing is detected by production of GFP protein, and green fluorescence in airway linings
|
-->
Repeat experiment of second site validation of Chen delivery platform using LNPs to deliver CRISPR/Cas9
-->
Delivery of CRISPR/Cas9 editor via bioreducible lipid nanoparticle to the inner ear in Ai14 mice
name -->
Repeat experiment of second site validation of Chen delivery platform using LNPs to deliver CRISPR/Cas9
-->
Repeat experiment of second site validation of Chen delivery platform using LNPs to deliver CRISPR/Cas9
Murray Stephen A
2021-04-01
Delivery of CRISPR/Cas9 editor via bioreducible lipid nanoparticle to the inner ear in Ai14 mice
|
-->
Second site validation of Chen delivery platform using LNPs to deliver CRISPR/Cas9 to mouse inner ear
-->
Delivery of CRISPR/Cas9 via bioreducible lipid nanoparticles (LNPs) to the inner ear in Ai14 mice
name -->
Second site validation of Chen delivery platform using LNPs to deliver CRISPR/Cas9 to mouse inner ear
-->
Second site validation of Chen delivery platform using LNPs to deliver CRISPR/Cas9 to mouse inner ear
Murray Stephen A
2021-04-01
Delivery of CRISPR/Cas9 via bioreducible lipid nanoparticles (LNPs) to the inner ear in Ai14 mice
|
-->
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 Cas9 to
name -->
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 Cas9 to
-->
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 Cas9 to
Asokan Aravind
2021-09-16
A dual vector strategy was employed: one delivering a single guide RNA and CB driven SaCas9, and another delivering the second guide RNA and CB driven SaCas9. This strategy was evaluted with both AAV9 (n=4) and AAVcc47 (n=5) by intravenous injection in Ai9 mice. A total dose of 2e12vg was injected into each mouse (1e12vg each vector mixed 1:1) and organs were harvested 4 weeks post injection. Editing efficency was determined by calculating percent TdTomato+ cells normalized to Dapi+ cells in liver and heart.
|
-->
Comparing CRISPR/Cas9 gene editing efficiencies between AAV9 and AAVcc47 in Ai9 mice with a 1:3 Cas9
name -->
Comparing CRISPR/Cas9 gene editing efficiencies between AAV9 and AAVcc47 in Ai9 mice with a 1:3 Cas9
-->
Comparing CRISPR/Cas9 gene editing efficiencies between AAV9 and AAVcc47 in Ai9 mice with a 1:3 Cas9
Asokan Aravind
2021-09-16
A dual vector strategy was employed: one delivering two single guide RNAs targeting the Rosa26 locus and one delivering CMV driven SaCas9 (both single stranded AAV cassettes). This strategy was evaluted with both AAV9 (n=4) and AAVcc47 (n=5) by intravenous injection in Ai9 mice. A total dose of 4e12vg was injected into each mouse and vectors mixed in a 1:4 ratio of cas9 to guide RNA (1e12vg of CMV Sacas9 vector and 3e12vg of the sgRNA vector) and organs were harvested 4 weeks post injection. Editing efficency was determined by calculating percent TdTomato+ cells normalized to Dapi+ cells in liver and heart.
|
-->
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 cas9 to
name -->
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 cas9 to
-->
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 cas9 to
Asokan Aravind
2021-09-16
A dual vector strategy was employed: one delivering two single guide RNAs targeting the Rosa26 locus and one delivering CMV driven SaCas9 (both single stranded AAV cassettes). This strategy was evaluted with both AAV9 (n=3) and AAVcc47 (n=3) by intravenous injection in Ai9 mice. A total dose of 3e12vg was injected into each mouse (1.5e12vg each vector mixed 1:1) and organs were harvested 4 weeks post injection. Editing efficency was determined by calculating percent TdTomato+ cells normalized to Dapi+ cells in liver and heart.
|
-->
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 Cas9 to
name -->
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 Cas9 to
-->
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 Cas9 to
Asokan Aravind
2021-09-16
A dual vector strategy was employed: one self complementary vector delivering two single guide RNAs targeting the Rosa26 locus and one delivering CMV driven SaCas9 (single stranded vector). This strategy was evaluted with both AAV9 (n=4) and AAVcc47 (n=4) by intravenous injection in Ai9 mice. A total dose of 4e12vg was injected into each mouse and vectors mixed in a 1:1 ratio of cas9 to guide RNA (2e12vg of CMV Sacas9 vector and 2e12vg of the self complementary sgRNA vector) and organs were harvested 4 weeks post injection. Editing efficency was determined by calculating percent TdTomato+ cells normalized to Dapi+ cells in liver and heart.
|
sNLS-SpCas9-sNLS
- Genome Editor 
- [In Vivo]
[Small Animal Testing Center (SATC), Delivery Systems Initiative]
[Mouse]
-->
Enabling Nanoplatforms for Targeted In Vivo Delivery of CRISPR/Cas9 Riboncleoproteins in the Brain
-->
Second site validation of Gong delivery platform using RNP-loaded nanocages to deliver CRISPR/Cas9 to
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain.
SpCas9 with N- and C-terminal SV40 NLS
|
Ai14 mouse
- Model System 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Enabling Nanoplatforms for Targeted In Vivo Delivery of CRISPR/Cas9 Riboncleoproteins in the Brain
-->
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain.
Ai14 mouse has a loxP-flanked STOP cassette preventing transcription of a CAG promoter-driven red fluorescent protein variant (tdTomato) - all inserted into the Gt(ROSA)26Sor locus. The att site flanked neo selection cassette has been removed in this strain.
|
CleanCap® Cas9 mRNA (5moU)
- Genome Editor 
- [In Vivo]
[Small Animal Testing Center (SATC)]
[Mouse]
-->
Repeat experiment of second site validation of Chen delivery platform using LNPs to deliver CRISPR/Cas9
Second site validation of Chen delivery platform using LNPs to deliver CRISPR/Cas9 to mouse inner ear
SpCas9 mRNA with 2 NLS signals, HA tag and capped using CleanCap. It is polyadenylated, substituted with a modified uridine and optimized for mammalian systems. It mimics a fully processed mature mRNA.
|
-->
Quantification of CRISPR/Cas editing in liver and heart following custom AAV-mediated delivery.
Heaney Jason D
2021-03-30
Quantification of CRISPR/Cas editing in liver and heart following custom AAV-mediated delivery. Detection of editing in non-target tissues.
|
RNP-NC-CPP
- Delivery System 
- [In Vivo]
[Small Animal Testing Center (SATC), Delivery Systems Initiative]
[Mouse]
-->
Enabling Nanoplatforms for Targeted In Vivo Delivery of CRISPR/Cas9 Riboncleoproteins in the Brain
-->
Second site validation of Gong delivery platform using RNP-loaded nanocages to deliver CRISPR/Cas9 to
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain.
The nanocapsule is a thin glutathione (GSH)-cleavable covalently crosslinked polymer coating around a preassembled ribonucleoprotein (RNP) complex between a Cas9 nuclease and an sgRNA. This nanoparticle has an addition of a cell penetrating peptide (CPP) from the TAT peptide (GRKKRRQRRRPQ) which lacks cell-type specficity
|
AB_2209751
- Antibody 
- [In Vivo]
[Small Animal Testing Center (SATC)]
[Mouse]
-->
Second site validation of Gong delivery platform using RNP-loaded nanocages to deliver CRISPR/Cas9 to
Other Id:
Rockland Cat# 600-401-379
Anti-RFP (RABBIT) Antibody
|
AB_141637
- Antibody 
- [In Vivo]
[Small Animal Testing Center (SATC)]
[Mouse]
-->
Second site validation of Gong delivery platform using RNP-loaded nanocages to deliver CRISPR/Cas9 to
Other Id:
A21207
Invitrogen, Donkey anti-rabbit alexa fluor 594
|
sg298
- Guide 
- [In Vivo]
[Small Animal Testing Center (SATC)]
[Mouse]
-->
Repeat experiment of second site validation of Chen delivery platform using LNPs to deliver CRISPR/Cas9
Second site validation of Chen delivery platform using LNPs to deliver CRISPR/Cas9 to mouse inner ear
This sgRNA targets the Ai9 and related transgenes at multiple sites. 2'-O-Methyl at 3 first and last bases, 3' phosphorothioate bonds between first 3 and last 2 bases
|
SpyCas9 g-loxP2_C9
- Guide 
- [In Vivo]
[Small Animal Testing Center (SATC)]
[Mouse]
-->
Validation for McCray Delivery Team: Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using
This sgRNA targets the mTmG transgene
|
D237
- Delivery System 
- [In Vivo]
[Small Animal Testing Center (SATC)]
[Mouse]
-->
Validation for McCray Delivery Team: Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using
|
AB_2532994
- Antibody 
- [In Vivo]
[Small Animal Testing Center (SATC)]
[Mouse]
-->
Second site validation of Gong delivery platform using RNP-loaded nanocages to deliver CRISPR/Cas9 to
Other Id:
13-0300
Thermo-Fisher, Rat anti-GFAP
|
AB_10711040
- Antibody 
- [In Vivo]
[Small Animal Testing Center (SATC)]
[Mouse]
-->
Second site validation of Gong delivery platform using RNP-loaded nanocages to deliver CRISPR/Cas9 to
Other Id:
ab104224
Abcam, mouse anti-NeuN
|
AB_2813835
- Antibody 
- [In Vivo]
[Small Animal Testing Center (SATC)]
[Mouse]
-->
Second site validation of Gong delivery platform using RNP-loaded nanocages to deliver CRISPR/Cas9 to
Other Id:
ab150155
Abcam, Donkey anti-rat alexa fluour 647
|
Ai14 mouse (congenic)
- Model System 
- [In Vivo]
[Small Animal Testing Center (SATC), Delivery Systems Initiative]
[Mouse]
-->
Repeat experiment of second site validation of Chen delivery platform using LNPs to deliver CRISPR/Cas9
Second site validation of Gong delivery platform using RNP-loaded nanocages to deliver CRISPR/Cas9 to
Second site validation of Chen delivery platform using LNPs to deliver CRISPR/Cas9 to mouse inner ear
Ai14 mouse has a loxP-flanked STOP cassette preventing transcription of a CAG promoter-driven red fluorescent protein variant (tdTomato) - all inserted into the Gt(ROSA)26Sor locus. The att site flanked neo selection cassette has been removed in this strain.
|
AAVcc47-Ai9-sgRNA1 + sgRNA2
- Vector 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 cas9 to
Comparing CRISPR/Cas9 gene editing efficiencies between AAV9 and AAVcc47 in Ai9 mice with a 1:3 Cas9
AAV serotype 9 delivering u6 promoter driving sgRNA 1 + sgRNA2 targeting the Ai9 locus
|
SaCas9-Lagor
- Genome Editor 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 cas9 to
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 Cas9 to
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 Cas9 to
Comparing CRISPR/Cas9 gene editing efficiencies between AAV9 and AAVcc47 in Ai9 mice with a 1:3 Cas9
|
-->
Validation of delivery of AAV custom designed to cross the blood-brain barrier for CRISPR/Cas9 editing
Heaney Jason D
2021-08-08
Validation of delivery of AAV custom designed to cross the blood-brain barrier for CRISPR/Cas9 editing. Editing detected and quantified in brain by generation of tdTomato fluorescent protein signal from Ai9 reporter mice
|
AAV9-Ai9-sgRNA1-CB-SaCas9
- Vector 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 Cas9 to
AAV serotype 9 delivering sgRNA 1 + CB SaCas9 targeting the Ai9 locus
|
AAV9-Ai9-sgRNA2-CB-SaCas9
- Vector 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 Cas9 to
AAV serotype 9 delivering gRNA 2 + CB SaCas9 targeting the Ai9 locus
|
-->
AAV5 encoding CRISPR/Cas editing machinery were delivered to the lungs of reporter mice by intratracheal
Heaney Jason D
2021-03-30
AAV5 encoding CRISPR/Cas editing machinery were delivered to the lungs of reporter mice by intratracheal instillation. After 4 weeks incubation, the mice were dissected and the lungs imaged for the presence of tdTomato fluorescence, indicating successful editing. Editing calculated by dividing the number of tdTomato+ red cells by the number of nuclei in each airway
|
306-O12B
- Delivery System 
- [In Vivo, In Vitro]
[Small Animal Testing Center (SATC), Delivery Systems Initiative]
[Mouse]
-->
Repeat experiment of second site validation of Chen delivery platform using LNPs to deliver CRISPR/Cas9
Second site validation of Chen delivery platform using LNPs to deliver CRISPR/Cas9 to mouse inner ear
Combinatorial library cationic lipid nanoparticles
|
306-S10
- Delivery System 
- [In Vivo, In Vitro]
[Small Animal Testing Center (SATC), Delivery Systems Initiative]
[Mouse]
-->
Second site validation of Chen delivery platform using LNPs to deliver CRISPR/Cas9 to mouse inner ear
combinatorial library cationic lipid nanoparticles
|
RNP-NC-no ligand
- Delivery System 
- [In Vivo]
[Small Animal Testing Center (SATC), Delivery Systems Initiative]
[Mouse]
-->
Enabling Nanoplatforms for Targeted In Vivo Delivery of CRISPR/Cas9 Riboncleoproteins in the Brain
-->
Second site validation of Gong delivery platform using RNP-loaded nanocages to deliver CRISPR/Cas9 to
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain.
The nanocapsule is a thin glutathione (GSH)-cleavable covalently crosslinked polymer coating around a preassembled ribonucleoprotein (RNP) complex between a Cas9 nuclease and an sgRNA.
|
Ai14 gRNA
- Guide 
- [In Vivo]
[Small Animal Testing Center (SATC), Delivery Systems Initiative]
[Mouse]
-->
Enabling Nanoplatforms for Targeted In Vivo Delivery of CRISPR/Cas9 Riboncleoproteins in the Brain
-->
Second site validation of Gong delivery platform using RNP-loaded nanocages to deliver CRISPR/Cas9 to
Enabling Nanoplatforms for Targeted in vivo Delivery of CRISPR/Cas9 Ribonucleoproteins in the Brain.
This sgRNA targets the Ai9 and related transgenes at multiple sites
|
mTmG mouse (congenic)
- Model System 
- [In Vivo]
[Small Animal Testing Center (SATC), Delivery Systems Initiative]
[Mouse]
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
-->
Validation for McCray Delivery Team: Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using
mTmG is a double-fluorescent reporter transgenic mouse which expresses membrane-targeted tdTomato flanked by loxP sequences, followed by membrane-targeted GFP. After genomic cleavage by Cas9 at two sites, or Cre recombinase between loxP sites, tdTomato expression is lost and GFP is expressed.
|
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
McCray Paul B
2020-11-02
Delivery of Cas9 RNP targeting human CFTR in Primary human epithelia cells. Gene editing efficiency was determined by percentage of NGS reads that showed an indel
|
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
McCray Paul B
2020-11-02
Delivery of GFP via shuttle peptides to mouse airway epithelium via nasal instilation. Delivery efficiency was quantified in large and small airways by counting the number of GFP positive cells divided by the number of DAPI cells.
|
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
McCray Paul B
2020-11-02
In Vitro shuttle peptide delivery of Cas12a RNPs targeting human CFTR and HPRT genes in human primary airway epithelia. Editing efficiency was assessed after 72hrs by sanger sequencing.
|
-->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
Gao Guang-Ping
2020-10-20
AAV shuttle plasmids expressing SpCas9 and guide RNAs targeting the Ai9 transgene were tested in HEK293T cells by transient transfection. Both delivery and gene editing were detected by fluorescence.
|
-->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
Gao Guang-Ping
2020-10-20
AAV2/5 mediated gene editing in the mouse airway was tested by deliverying SpCas9 and guide RNAs targeting the Ai9 transgene in Ai9 transgenic mice. Viral delivery was detected by GFP expression and gene editing quantified by tdTomato activation
|
AsCas12a (Feldan Therapeutics)
- Genome Editor 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
|
FSD116d1
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD168 cyclic
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD168d11
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD168d20
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide
|
FSD222
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD239
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD283
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD297
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD301
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD315
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD321
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD329
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD333
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD361
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD363
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD57
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD57d5
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD97
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSX8
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
S10 Scr.
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
S18
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide
|
-->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
AAV2/5 expressing SpyCas9. AAV2/5 expressing two sgRNAs under U6 promoter and eGFP
|
g-loxP2_C9
- Guide 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
This sgRNA targets the Ai9 and related transgenes
|
NKG2A
- Guide 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
gRNA targeting human NKG2A exon 3
|
sgAi9L
- Guide 
- [In Vivo, In Vitro]
[Delivery Systems Initiative]
[Human, Mouse]
-->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
This sgRNA targets the Ai9 and related transgenes
|
NK
- Model System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
|
Primary Airway Epithelia
- Model System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Primary airway epithelia from non-CF donors
|
-->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
Gao Guang-Ping
2021-09-21
AAV2/5 mediated gene editing in the mouse airway was tested by deliverying SpCas9 and guide RNAs targeting the Ai9 transgene in Ai9 transgenic mice. Gene editing quantified by tdTomato activation and cell specific markers for club and ciliated cell types.
|
Alt-R® S.p. Cas9 Nuclease V3
- Genome Editor 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
|
FSD112
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD114d1
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD168
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD168d17
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD186
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD188
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD193
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD228
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD235
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD236
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD260
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD286
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD293
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD307
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD308
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD318
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD335
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD341
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD362
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD365
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD366
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD67
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD95
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSX5
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
S10D
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
McCray_CFTR_Cas9_Guide1
- Guide 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Targets endogenous human locus
|
mTmG mouse
- Model System 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
ROSAmT/mG is a cell membrane-targeted, two-color fluorescent Cre-reporter allele. Prior to Cre recombination, cell membrane-localized tdTomato (mT) fluorescence expression is widespread in cells/tissues. Cre recombinase expressing cells (and future cell lineages derived from these cells) have cell membrane-localized EGFP (mG) fluorescence expression replacing the red fluorescence
|
- Antibody 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
Other Id:
Thermo Fisher Scientific, MA5-15257
Anti-RFP (Mouse) Monoclonal Antibody, dilution used 1:300
|
- Antibody 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
Other Id:
Rockland, 600- 401-379
Anti-RFP (Rabbit) Polyclonal Antibody
|
Lipofectamine 3000
- Delivery System 
- [In Vitro]
[Genome Editors, Delivery Systems Initiative]
[Human]
-->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Lipid nanoparticle
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Sontheimer Erik J
2021-10-01
Delivery of chemically modified, phosphorothioate (PS)-stabilized crRNA with chemically modified, PS-stabilized tracrRNA to activate the mTmG reporter in mouse brain
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Sontheimer Erik J
2021-04-15
Chemically modified crRNA and tracrRNA were delivered by electroporation to mouse Hepa 1-6 cells. Editing activity was determined by Sanger sequencing
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Sontheimer Erik J
2021-04-15
Chemically modified crRNA and tracrRNA were injected into the intra-striatum of mTmG reporter mice and activation of GFP expression was imaged.
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Sontheimer Erik J
2021-04-15
Chemically modified crRNA and tracrRNA were delivered by electroporation to transgenic human HEK-293T cells harboring the TLR1 reporter. Gene editing was determined by reporter activation.
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Targets endogenous mouse locus
|
STS159 (mTmG; Sp_t2:Sp_c0_mTmG)
- Guide 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Targets mTmG and related reporter transgenes
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
For endogenous locus
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Targets endogenous mouse locus
|
Neuro 2A
- Model System 
- [In Vitro]
[Delivery Systems Initiative]
[Mouse]
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Stable cell line
|
S10
- Delivery System 
- [In Vivo, In Vitro]
[Delivery Systems Initiative]
[Human, Mouse]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Shuttle peptide used to deliver reagents to airway epithelia
|
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
McCray Paul B
2020-11-02
In vivo shuttle peptide delivery of Cas9 and Cas12a RNPs in mouse airway epithelia. Gene editing was quantified by the GFP+ cells in large and small airways following 1 delivery of GFP protein by GFP positive cells compared to DAPI stained cells.
|
Cre recombinase
- Genome Editor 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
Cre recombinase delivered by plasmid (see vector details)
|
GFP-NLS
- Genome Editor 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Nuclear targeted GFP
|
CM18-PTD4
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide
|
FSD114
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD115
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD160
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD168 Disul.
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD168 Scr.
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD190
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD196
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD215
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD227
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD238
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD259
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD304
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD305
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD306
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD332
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD364
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD57d6
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSX2
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSX4
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSX6
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
S85
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide
|
AAV.pU1a-SpCas9
- Vector 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
Expresses codon-optimized SpCas9 in mammalian cells. HA-SV40NLS-SpCas9-SV40NLS
|
-->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
AAV2/5 expressing SpyCas9. AAV2/5 expressing two sgRNAs under U6 promoter and eGFP
|
3849 45-5'
- Guide 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Targets endogenous human locus
|
-->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
HEK-293T cells transfected with an Ai9 inducible transgene reporter plasmid used to test gene editing activity by fluorescence
|
- Antibody 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
Other Id:
Rockland Cat# 600-401-379
Anti-RFP (RABBIT) Antibody
|
- Antibody 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
Other Id:
Santa Cruz, SC-25555
Anti-CC10 (Rabbit) Polyclonal Antibody, dilution used 1:2,000
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Sontheimer Erik J
2021-04-15
Chemically modified crRNA and tracrRNA were injected into the intra-striatum of mTmG reporter mice and activation of GFP expression was imaged.
|
SpyCas9-3xNLS
- Genome Editor 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
SpyCas9-3xNLS is type II-A Cas9 from Streptococcus pyogenes strain SF370. It was expressed from
pMCSG7 bacterial expressing vector and purified from Escherichia coli Rosetta DE3 strain.
SpyCas9 fused to 3 NLS:
C-Myc-like NLS at the N-terminal
SV40 NLS and Nucleoplasmin NLS at the C-terminal
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Targets traffic light reporter transgene, CY3 labeled
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Targets traffic light reporter transgene
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Targets endogenous mouse locus
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Targets mTmG and related reporter transgenes
|
RNP-NC-RVG
- Delivery System 
- [In Vivo]
[Small Animal Testing Center (SATC)]
[Mouse]
-->
Second site validation of Gong delivery platform using RNP-loaded nanocages to deliver CRISPR/Cas9 to
The nanocapsule is a thin glutathione (GSH)-cleavable covalently crosslinked polymer coating around a preassembled ribonucleoprotein (RNP) complex between a Cas9 nuclease and an sgRNA. This nanoparticle has an addition of a RVG peptide YTIWMPENPRPGTPCDIFTNSRGKRASNG which specifically interacts withthe N-acetylecholine receptor (AchR) on neuronal cells, which mediates NP entry
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Sontheimer Erik J
2021-04-15
Chemically modified crRNA and tracrRNA were injected into the intra-striatum of mTmG reporter mice and activation of GFP expression was imaged.
|
SpyCas9-3xNLS
- Genome Editor 
- [In Vivo, In Vitro]
[Delivery Systems Initiative]
[Human, Mouse]
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
SpyCas9-3xNLS is type II-A Cas9 from Streptococcus pyogenes strain SF370. It was expressed from
pMCSG7 bacterial expressing vector and purified from Escherichia coli Rosetta DE3 strain.
SpyCas9 fused to 3 NLS:
C-Myc-like NLS at the N-terminal
SV40 NLS and Nucleoplasmin NLS at the C-terminal
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Targets mTmG and related reporter transgenes
|
Hepa1-6
- Model System 
- [In Vitro]
[Delivery Systems Initiative]
[Mouse]
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Stable cell line
|
TLR-MCV1
- Model System 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
TLR-MCV1 transgene knocked into Rosa26 locus
|
RRID:AB_1196615
- Antibody 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Other Id:
AB_1196615
GFP (D5.1) XP Rabbit mAb antibody, Cell Signaling Technology
|
D10
- Delivery System 
- [In Vivo]
[Small Animal Testing Center (SATC)]
[Mouse]
-->
Validation for McCray Delivery Team: Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using
|
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
McCray Paul B
2020-11-02
Delivery of Cas12a RNP targeting human CFTR in Primary human epithelia cells. Gene editing efficiency was determined by percentage of NGS reads that showed an indel
|
FS48
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FS66d6
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD115d1
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD118
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD132
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD168d12
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD189
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD191
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD195
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD234
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD284
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD285
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD288
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD289
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD291
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD303
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD310
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD317
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD322
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD330
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD331
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD347
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD360
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD367
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD57d1
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD57d4
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD63D1
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD94
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSD96
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
FSX3
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Shuttle peptide used to deliver reagents to airway epithelia
|
g-11_C9
- Guide 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
sgRNA targeting CFTR exon 11
|
g-38330_C12a
- Guide 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
gRNA targeting HPRT locus
|
g-45_C12a
- Guide 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
gRNA targeting CFTR inton-22-23
|
sgAi9R
- Guide 
- [In Vivo, In Vitro]
[Delivery Systems Initiative]
[Human, Mouse]
-->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
This sgRNA targets the Ai9 and related transgenes
|
BALB/c mouse
- Model System 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
BALB/cJ is a commonly used inbred. Key traits include a susceptibility to developing the demyelinating disease upon infection with Theiler's murine encephalomyelitis virus. The BALB/cJ substrain is susceptible to Listeria, all species of Leishmania, and several species of Trypanosoma, but is resistant to experimental allergic orchitis (EAO).
|
- Antibody 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Develop Combinatorial Non-Viral and Viral CRISPR Delivery for Lung Diseases
Other Id:
Santa Cruz, SC-23950
Anti-alpha Tubulin (Mouse) Monoclonal Antibody, dilution used 1:200
|
AAV9-Ai9-sgRNA1 + sgRNA2
- Vector 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 cas9 to
Comparing CRISPR/Cas9 gene editing efficiencies between AAV9 and AAVcc47 in Ai9 mice with a 1:3 Cas9
AAV serotype 9 delivering u6 promoter driving sgRNA 1 + sgRNA2 targeting the Ai9 locus
|
AAVcc47-CMV-SaCas9
- Vector 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 cas9 to
Comparing CRISPR/Cas9 gene editing efficiencies between AAV9 and AAVcc47 in Ai9 mice with a 1:3 Cas9
AAVcc47 delivering CMV driven SaCas9
|
306-O12B blank
- Delivery System 
- [In Vivo]
[Small Animal Testing Center (SATC)]
[Mouse]
-->
Repeat experiment of second site validation of Chen delivery platform using LNPs to deliver CRISPR/Cas9
Combinatorial library cationic lipid nanoparticles
|
AB_141607
- Antibody 
- [In Vivo]
[Small Animal Testing Center (SATC)]
[Mouse]
-->
Second site validation of Gong delivery platform using RNP-loaded nanocages to deliver CRISPR/Cas9 to
Other Id:
A21202
Invitrogen, Donkey anti-mouse alexafluor 488
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Sontheimer Erik J
2021-04-15
Chemically modified crRNA and tracrRNA were delivered by electroporation to embryonic fibroblasts harvested from the mTmG reporter mouse. Gene editing was determined by reporter activation.
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Sontheimer Erik J
2021-04-15
Chemically modified crRNA and tracrRNA were delivered by electroporation in presence of amphiphilic peptide to transgenic human HEK-293T cells harboring the TLR-MCV1 reporter. Gene editing was determined by reporter activation.
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Sontheimer Erik J
2021-04-15
Chemically modified crRNA and tracrRNA were delivered by electroporation to mouse Neuro2A cells. Editing activity was determined by Sanger sequencing
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Targets traffic light reporter transgene
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Targets traffic light reporter transgene
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Targets endogenous mouse locus
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Targets endogenous mouse locus
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
HEK293T cells with an integrated reporter for TLR1 reporter editing
|
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
HEK293T cells with an integrated reporter for TLR-MCV1 reporter editing
|
RRID:AB_2798820
- Antibody 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Other Id:
AB_2798820
Cas9 (S. pyogenes) (E7M1H) XP® Rabbit mAb antibody, Cell Signaling Technology
|
RRID:AB_2536526
- Antibody 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Other Id:
AB_2536526
GFP Recombinant Rabbit Monoclonal Antibody, Thermo Fisher Scientific #G10362
|
CasΦ-1
- Genome Editor 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Compact editor of the Cas12j family identified in biggie phage from metagenomic assemblies
|
Cas12j-GFP11 (CasΦ-3)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Guide targeting eGFP compatible with CasΦ-3
|
Cas12j-GFP16 (CasΦ-1)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Guide targeting eGFP compatible with CasΦ-1
|
Cas12j-GFP1 (CasΦ-2)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Guide targeting eGFP compatible with CasΦ-2
|
Cas12j-GFP20 (CasΦ-1)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Guide targeting eGFP compatible with CasΦ-1
|
Cas12j-GFP2 (CasΦ-1)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Guide targeting eGFP compatible with CasΦ-1
|
Cas12j-GFP3 (CasΦ-1)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Guide targeting eGFP compatible with CasΦ-1
|
Cas12j-GFP4 (CasΦ-2)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Guide targeting eGFP compatible with CasΦ-2
|
Cas12j-GFP7 (CasΦ-3)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Guide targeting eGFP compatible with CasΦ-3
|
Cas12j-GFP8 (CasΦ-3)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Guide targeting eGFP compatible with CasΦ-3
|
Cas12j-GFP9 (CasΦ-3)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Guide targeting eGFP compatible with CasΦ-3
|
FSD117D1
- Delivery System 
- [In Vitro]
[Delivery Systems Initiative]
[Human]
-->
Delivery of CRISPR Ribonucleoproteins to Airway Epithelia Using Novel Amphiphilic Peptides
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
Shuttle peptide used to deliver reagents to airway epithelia
|
AAV9-CMV-SaCas9
- Vector 
- [In Vivo]
[Delivery Systems Initiative]
[Mouse]
-->
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 cas9 to
Comparing CRISPR/Cas9 gene editing efficencies between AAV9 and AAVcc47 in Ai9 mice with a 1:1 Cas9 to
Comparing CRISPR/Cas9 gene editing efficiencies between AAV9 and AAVcc47 in Ai9 mice with a 1:3 Cas9
AAV serotype 9 delivering CMV driven SaCas9
|
Cas12j-GFP12 (CasΦ-3)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Guide targeting eGFP compatible with CasΦ-3
|
Cas12j-GFP13 (CasΦ-3)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Guide targeting eGFP compatible with CasΦ-3
|
Cas12j-GFP17 (CasΦ-1)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Guide targeting eGFP compatible with CasΦ-1
|
Cas12j-GFP18 (CasΦ-1)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Guide targeting eGFP compatible with CasΦ-1
|
SapI-GG stuffer (CasΦ-1)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Non-targeting guide RNA targeting compatible with CasΦ-1
|
SapI-GG stuffer (CasΦ-2)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Non-targeting guide RNA targeting compatible with CasΦ-2
|
SapI-GG stuffer (CasΦ-3)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Non-targeting guide RNA targeting compatible with CasΦ-3
|
pPP441
- Vector 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Plasmid containing Homo sapiens codon optimized CasΦ-2 and spacer for editing in human cells.
|
pPP444
- Vector 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Plasmid containing Homo sapiens codon optimized CasΦ-3 and spacer for editing in human cells.
|
Cas12j-GFP10 (CasΦ-3)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
Guide targeting eGFP compatible with CasΦ-3
|
Cas12j-GFP14 (CasΦ-3)
- Guide 
- [In Vitro]
[Genome Editors]
[Human]
-->
Expanding CRISPR-Cas Editing Technology through Exploration of Novel Cas Proteins and DNA Repair Systems
< |